T.M. Sanger

5.3k total citations · 1 hit paper
69 papers, 4.1k citations indexed

About

T.M. Sanger is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, T.M. Sanger has authored 69 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Psychiatry and Mental health, 25 papers in Pharmacology and 9 papers in Cognitive Neuroscience. Recurrent topics in T.M. Sanger's work include Schizophrenia research and treatment (36 papers), Bipolar Disorder and Treatment (25 papers) and Treatment of Major Depression (25 papers). T.M. Sanger is often cited by papers focused on Schizophrenia research and treatment (36 papers), Bipolar Disorder and Treatment (25 papers) and Treatment of Major Depression (25 papers). T.M. Sanger collaborates with scholars based in United States, Canada and Netherlands. T.M. Sanger's co-authors include Gary D. Tollefson, Charles M. Beasley, S.H. Hamilton, W. Satterlee, P. Tran, Mauricio Tohen, Starr L. Grundy, S. Corya, Yili Lu and Michael Case and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and The British Journal of Psychiatry.

In The Last Decade

T.M. Sanger

68 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olanzapine versus Placebo and Haloperidol

1996 643 citations Charles M. Beasley, Gary D. Tollefson et al. Neuropsychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T.M. Sanger United States	26	3.3k	1.2k	555	521	384	69	4.1k
Joseph Peuskens Belgium	37	3.4k 1.0×	676 0.5×	697 1.3×	638 1.2×	342 0.9×	147	4.6k
Franca Centorrino United States	30	3.6k 1.1×	770 0.6×	703 1.3×	291 0.6×	420 1.1×	58	4.6k
George M. Simpson United States	39	3.1k 0.9×	721 0.6×	889 1.6×	493 0.9×	404 1.1×	154	4.4k
Martina Hummer Austria	31	2.9k 0.9×	461 0.4×	681 1.2×	686 1.3×	220 0.6×	69	3.7k
S.H. Hamilton United States	18	2.4k 0.7×	725 0.6×	483 0.9×	598 1.1×	210 0.5×	41	3.0k
Raymond Sanchez United States	31	2.6k 0.8×	1.0k 0.8×	498 0.9×	284 0.5×	223 0.6×	68	3.3k
Jean-Pierre Lindenmayer United States	29	2.9k 0.9×	424 0.3×	840 1.5×	501 1.0×	544 1.4×	43	4.0k
William C. Wirshing United States	31	2.8k 0.8×	426 0.3×	824 1.5×	665 1.3×	427 1.1×	90	3.9k
Robert Lasser United States	33	3.4k 1.0×	927 0.7×	1.0k 1.8×	1.1k 2.0×	408 1.1×	94	4.8k
Martin Brecher United States	28	3.3k 1.0×	903 0.7×	489 0.9×	175 0.3×	137 0.4×	74	3.9k

Countries citing papers authored by T.M. Sanger

Since Specialization

Citations

This map shows the geographic impact of T.M. Sanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T.M. Sanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T.M. Sanger more than expected).

Fields of papers citing papers by T.M. Sanger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T.M. Sanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T.M. Sanger. The network helps show where T.M. Sanger may publish in the future.

Co-authorship network of co-authors of T.M. Sanger

This figure shows the co-authorship network connecting the top 25 collaborators of T.M. Sanger. A scholar is included among the top collaborators of T.M. Sanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T.M. Sanger. T.M. Sanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Min, T.M. Sanger, & Xiong Liu. (2019). Combining Contextualized Embeddings and Prior Knowledge for Clinical Named Entity Recognition: Evaluation Study. JMIR Medical Informatics. 7(4). e14850–e14850. 24 indexed citations

Thase, Michael E., S. Corya, Olawale Osuntokun, et al.. (2007). A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder. The Journal of Clinical Psychiatry. 68(2). 224–236. 171 indexed citations

Corya, S., et al.. (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and Anxiety. 23(6). 364–372. 129 indexed citations

Shelton, Richard C., Douglas J. Williamson, S. Corya, et al.. (2005). Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 66(10). 1289–1297. 130 indexed citations

Keefe, Richard S.E., Larry J. Seidman, Bruce K. Christensen, et al.. (2005). Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis. Biological Psychiatry. 59(2). 97–105. 94 indexed citations

Keefe, Richard S.E., Larry J. Seidman, Bruce K. Christensen, et al.. (2004). Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol. American Journal of Psychiatry. 161(6). 985–995. 243 indexed citations

Mallinckrodt, Craig, T.M. Sanger, Sanjay Dubé, et al.. (2003). Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biological Psychiatry. 53(8). 754–760. 188 indexed citations

Kennedy, John, Dilip V. Jeste, Christopher Kaiser, et al.. (2003). Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial. International Journal of Geriatric Psychiatry. 18(11). 1013–1020. 30 indexed citations

Corya, S., Scott W. Andersen, Holland C. Detke, et al.. (2003). Long-Term Antidepressant Efficacy and Safety of Olanzapine/Fluoxetine Combination. The Journal of Clinical Psychiatry. 64(11). 1349–1356. 55 indexed citations

10.

Sanger, T.M., Mauricio Tohen, Eduard Vieta, et al.. (2002). Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. Journal of Affective Disorders. 73(1-2). 155–161. 50 indexed citations

11.

Perry, Paul J., Brian C. Lund, T.M. Sanger, & Charles M. Beasley. (2001). Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial. Journal of Clinical Psychopharmacology. 21(1). 14–20. 109 indexed citations

12.

Tohen, Mauricio, Fan Zhang, Cindy C. Taylor, et al.. (2001). A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. Journal of Affective Disorders. 65(1). 85–93. 49 indexed citations

13.

Sanger, T.M., et al.. (2001). Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder. The Journal of Clinical Psychiatry. 62(4). 273–281. 78 indexed citations

14.

Chengappa, KN Roy, Mauricio Tohen, Joseph Levine, et al.. (2000). Response to placebo among bipolar I disorder patients experiencing their first manic episode. Bipolar Disorders. 2(4). 332–335. 6 indexed citations

15.

Tohen, Mauricio, T.M. Sanger, Susan L. McElroy, et al.. (1999). Olanzapine Versus Placebo in the Treatment of Acute Mania. American Journal of Psychiatry. 156(5). 702–709. 443 indexed citations

16.

Trân, Pierre V., Gary D. Tollefson, T.M. Sanger, et al.. (1999). Olanzapineversushaloperidol in the treatment of schizoaffective disorder. The British Journal of Psychiatry. 174(1). 15–22. 54 indexed citations

17.

Tollefson, Gary D., et al.. (1998). Depressive Signs and Symptoms in Schizophrenia. Archives of General Psychiatry. 55(3). 250–250. 200 indexed citations

18.

Perry, Paul J., T.M. Sanger, & Charles M. Beasley. (1997). Olanzapine Plasma Concentrations and Clinical Response in Acutely Ill Schizophrenic Patients. Journal of Clinical Psychopharmacology. 17(6). 472–477. 91 indexed citations

19.

Beasley, Charles M., T.M. Sanger, W. Satterlee, et al.. (1996). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 124(1-2). 159–167. 320 indexed citations

20.

Beasley, Charles M., Gary D. Tollefson, P. Tran, et al.. (1996). Olanzapine versus Placebo and Haloperidol. Neuropsychopharmacology. 14(2). 111–123. 643 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact